Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChonlaphat Sukasemen_US
dc.contributor.authorV. Churdbooncharten_US
dc.contributor.authorS. Chasombaten_US
dc.contributor.authorS. Kohreanudomen_US
dc.contributor.authorChotip Watitpunen_US
dc.contributor.authorWantanich Pirojen_US
dc.contributor.authorMontip Tiensuwanen_US
dc.contributor.authorWasun Chantratitaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.identifier.citationJournal of Chemotherapy. Vol.19, No.5 (2007), 528-535en_US
dc.description.abstractTo determine the prevalence of antiretroviral resistance in treatment-failure HIV-1 infected individuals, under the initiative of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen in Thailand, plasma samples were collected from 1,376 HIV-1 infected patients, who were failing in their current HAART therapy during 2000-2004. They were stratified into 2 intervals: group one (1), 558 HIV-1 infected patients (2000-2002; before the initiative of access to HAART), and group two (2), 818 HIV-1 infected patients (2003-2004; after the initiative of access to HAART). Genotypic resistance testing was performed. The frequency of antiretroviral drug resistance in treatment-failure HIV-1 infected patients has significantly increased over time from 68.5% (382/558) during 2000-2002 to 74.9% (613/818) during 2003-2004 (P<0.01). Resistance to NNRTI during 2003-2004 (59.2%) was much higher than that during 2000-2002 (36.9%; P<0.001). However, the frequency of nucleoside reverse transcriptase inhibitor (NRTI) drug resistance was not significantly higher (P=0.153). We showed that this correlated with an increase in the NNRTI-based regimen prescribed during 2003-2004, especially the Thai-produced combination pill, GPO-VIR. Our finding also showed that a high level of genotypic drug resistance is associated with GPO-VIR (40.8% lamivudine, 40.6% stavudine, 43.8% nevirapine). In order to avoid the rapid emergence of resistant viruses in a resource-poor setting, a close surveillance of antiretroviral drug resistance is feasible and should be considered. © E.S.I.F.T. srl.en_US
dc.rightsMahidol Universityen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePrevalence of antiretroviral drug resistance in treated HIV-1 infected patients: Under the initiative of access to the NNRTI-based regimen in Thailanden_US
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.